

## Precision Medicine Infrastructure linked to Science and Technology (IMPaCT) The IMPact Genomic programme for the diagnosis of rare disease in Spain



Ángel Carracedo

Galician Foundation of Genomic Medicine







CONFERENCE

Rare diseases and European Reference Networks: How to ensure European solidarity for patients?













### **IMPaCT-GENOMICS**

Genomic infrastructure (with IMPaCT Cohort and IMPacT Data) desgined to be the basis for the implementation of Personalized Medicine in the Spanish National Health System

- Equal access of "high complexity" genomic diagnosis in udiagnosed cases (beyond the standard of care)
- -Generation of high quality genomic data to be used in research as contribution to the 1+M Genomes Initiative
- -Actionable biomarkers (proven clinical utility)

Use cases: Rare diseases, cancer and pharmacogenomics & population genomics (in coordination with IMPaCT cohort)





Sequencing centers (CNAG/FPGMX/NB)

Coordination - management

Regional coordinators

Hospital network

- WP3- Rare diseases
- WP4- Cancer
- WP5- Pharmacogenomics

17 CCAA

37 associated institutions


110 hospitals

3 sequencing centers


20 working goups


9 groups of experts

>350 collaborators



Informed consent model allowing the use for research and shareability of clinical and genomic data Approved by the ISCIII EC and local ECs Mandatory for patient's inclusion in the program Additional IC for diagnosis (model offered to centers) Signature of MTA/DTA (mandatory)







### DIAGNOSIS REPORT MODEL



### **HPO PHENOTYPING**



# Rare diseases working groups

### FUNCTIONAL VALIDATION



### **EXPERT COMMITTEES**



## STORAGE AND DATA SHARING





- Pathol. Categories , (ORPHA/OMIM)
- **Genes** (GeneID)
- Diagnoses procedures
- Functional validation network
- > 400 experts
  - + 1500 genes OMIM/Orph
  - + 1500 disease in 16 categories










### CASES BY CCAA – POPULATION CRITERIA



### **SEQUENCING EFFORTS**

### **UNDIAGNOSED RARE DISEASES**

3000 WGS (Cases and tríos) Exome reanalysis success 12% Disgnosis rate (estimated) 20-23% Average undiagnosed time: 9 years

#### **CANCER**

Undiagnosed inherited cancer and unkown primary (as a model of standards for somatic mutations)

#### **PHARMACOGENOMICS**

Clinical guidelines, proficiency testing, pilot projects **Population genomics**: Standards for PRS (breats cancer as model)







### ¿CÓMO PARTICIPAR?





Para conocer cómo solicitar la participación en el programa por favor revisa la siguiente documentación según corresponda:


Enfermedades raras

Cáncer hereditario

Cáncer primario de origen desconocido


etro acrapso.





Cáncer hereditario

Cáncer primario de origen desconocido
















Flow chart simples/data



centers





**Proficiency Testing** 







Patient association alliance



6 Expert committees


Informed consents MTA/DTA Gobernance



Case selection



**Analisis of** data



IMPa( 8 workshops



Plataform for clinical data maangement



Project manager team



Clinical guidelines

Dissemination



Diagnostic report model



>200 meetings





